- Synthesis of ranolazine metabolites and their anti-myocardial ischemia activities
-
The anti-anginal drug Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, is thought to modulate the metabolism during myocardial ischemia by activating pyruvate dehydrogenase activity to promote glucose oxidation. Ranolazine and its five principal metabolites: CVT-2512, CVT-2513, CVT-2514, CVT-2738 and CVT-4786, were synthesized. The effect of Ranolazine and its metabolites on the ECG (electrocardiogram) of mice with myocardial ischemia induced by isoprenaline and their effect on alleviating the symptom of myocardial ischemia were tested and compared. The results showed that CVT-2738 and CVT-2513 could be protective against mice myocardial ischemia induced by isoprenaline. Within all the metabolites tested in this study, CVT-2738 exhibited the best potency, however, it was still less potent than Ranolazine.
- Yao, Zhangyu,Gong, Shubo,Guan, Teng,Li, Yunman,Wu, Xiaoming,Sun, Hongbin
-
experimental part
p. 1218 - 1222
(2010/06/16)
-
- A facile synthesis of aryl spirodioxines based on a 3H,3′H-2, 2′-spiro-bi(benzo[b][1,4]dioxine) skeleton
-
The synthesis of a series of 6,6-bisbenzannulated spiroketals containing a 3H,3′H-2,2′-spirobi(benzo[b][1,4]dioxine) ring system is reported. The key step involves addition of a monobenzyl-protected catechol to the epoxide unit of a glycidol bearing a benzyl-protected catechol. The resultant alcohol adduct is oxidized to a ketone that then undergoes hydrogenation and acid-catalyzed cyclization to produce the desired spirodioxines. Georg Thieme Verlag Stuttgart.
- Brimble, Margaret A.,Liu, Yen-Cheng,Trzoss, Michael
-
p. 1392 - 1402
(2008/02/12)
-